Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

RET Office Locations

RET has an office in Rotterdam
Rotterdam, NL (HQ)
Laan op Zuid 2
Show all (1)

RET Financials and Metrics

Summary Metrics

Founding Date

1878

RET Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

RET Online and Social Media Presence

Embed Graph

RET News and Updates

Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress

INDIANAPOLIS, April 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo® (selpercatinib 40 mg & 80 mg capsules) in patients with RET fusion-positive non-small cell lung cancer (NSCLC). Retevmo (marketed as...

European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer

Basel, 19 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has granted conditional marketing authorisation for Gavreto® (pralsetinib) as a monotherapy for the treatment of adults with rearranged during transfection (RET) fusion-positive advanced no…

Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor

Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor

Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer

Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged d…

RET Frequently Asked Questions

  • When was RET founded?

    RET was founded in 1878.

  • How many employees does RET have?

    RET has 1,809 employees.

  • Who are RET competitors?

    Competitors of RET include Traxión, Autostrade Per L'Italia and CFI.

  • Where is RET headquarters?

    RET headquarters is located at Laan op Zuid 2, Rotterdam.

  • Where are RET offices?

    RET has an office in Rotterdam.

  • How many offices does RET have?

    RET has 1 office.